713 related articles for article (PubMed ID: 26863353)
1. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
Peyvandi F; Scully M; Kremer Hovinga JA; Cataland S; Knöbl P; Wu H; Artoni A; Westwood JP; Mansouri Taleghani M; Jilma B; Callewaert F; Ulrichts H; Duby C; Tersago D;
N Engl J Med; 2016 Feb; 374(6):511-22. PubMed ID: 26863353
[TBL] [Abstract][Full Text] [Related]
2. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
Scully M; Cataland SR; Peyvandi F; Coppo P; Knöbl P; Kremer Hovinga JA; Metjian A; de la Rubia J; Pavenski K; Callewaert F; Biswas D; De Winter H; Zeldin RK;
N Engl J Med; 2019 Jan; 380(4):335-346. PubMed ID: 30625070
[TBL] [Abstract][Full Text] [Related]
3. Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura.
Hollifield AL; Arnall JR; Moore DC
Am J Health Syst Pharm; 2020 Jul; 77(15):1201-1207. PubMed ID: 32588878
[TBL] [Abstract][Full Text] [Related]
4. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.
Peyvandi F; Scully M; Kremer Hovinga JA; Knöbl P; Cataland S; De Beuf K; Callewaert F; De Winter H; Zeldin RK
J Thromb Haemost; 2017 Jul; 15(7):1448-1452. PubMed ID: 28445600
[TBL] [Abstract][Full Text] [Related]
5. Real-world experience with caplacizumab in the management of acute TTP.
Dutt T; Shaw RJ; Stubbs M; Yong J; Bailiff B; Cranfield T; Crowley MP; Desborough M; Eyre TA; Gooding R; Grainger J; Hanley J; Haughton J; Hermans J; Hill Q; Humphrey L; Lowe G; Lyall H; Mohsin M; Nicolson PLR; Priddee N; Rampotas A; Rayment R; Rhodes S; Taylor A; Thomas W; Tomkins O; Van Veen JJ; Lane S; Toh CH; Scully M
Blood; 2021 Apr; 137(13):1731-1740. PubMed ID: 33150355
[TBL] [Abstract][Full Text] [Related]
6. Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura.
Poullin P; Bornet C; Veyradier A; Coppo P
Drugs Today (Barc); 2019 Jun; 55(6):367-376. PubMed ID: 31250841
[TBL] [Abstract][Full Text] [Related]
7. Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment.
le Besnerais M; Veyradier A; Benhamou Y; Coppo P
Expert Opin Biol Ther; 2019 Nov; 19(11):1127-1134. PubMed ID: 31359806
[No Abstract] [Full Text] [Related]
8. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.
Goshua G; Sinha P; Hendrickson JE; Tormey C; Bendapudi PK; Lee AI
Blood; 2021 Feb; 137(7):969-976. PubMed ID: 33280030
[TBL] [Abstract][Full Text] [Related]
9. Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura.
Elverdi T; Eskazan AE
Drug Des Devel Ther; 2019; 13():1251-1258. PubMed ID: 31118566
[TBL] [Abstract][Full Text] [Related]
10. Caplacizumab for relapsing thrombotic thrombocytopenic purpura.
Kaczmarek V; Holle J; Astudillo R; Kempf C; Bufler P; Müller D
Pediatr Nephrol; 2019 Sep; 34(9):1625-1628. PubMed ID: 31177334
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study.
Knoebl P; Cataland S; Peyvandi F; Coppo P; Scully M; Kremer Hovinga JA; Metjian A; de la Rubia J; Pavenski K; Minkue Mi Edou J; De Winter H; Callewaert F
J Thromb Haemost; 2020 Feb; 18(2):479-484. PubMed ID: 31691462
[TBL] [Abstract][Full Text] [Related]
12. A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura.
Gómez-Seguí I; Fernández-Zarzoso M; de la Rubia J
Expert Rev Hematol; 2020 Nov; 13(11):1153-1164. PubMed ID: 32876503
[No Abstract] [Full Text] [Related]
13. A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP.
Coppo P; Bubenheim M; Azoulay E; Galicier L; Malot S; Bigé N; Poullin P; Provôt F; Martis N; Presne C; Moranne O; Benainous R; Dossier A; Seguin A; Hié M; Wynckel A; Delmas Y; Augusto JF; Perez P; Rieu V; Barbet C; Lhote F; Ulrich M; Rumpler AC; de Witte S; Krummel T; Veyradier A; Benhamou Y
Blood; 2021 Feb; 137(6):733-742. PubMed ID: 33150928
[TBL] [Abstract][Full Text] [Related]
14. Thrombotic Thrombocytopenic Purpura: Beyond Empiricism and Plasma Exchange.
Tsai HM
Am J Med; 2019 Sep; 132(9):1032-1037. PubMed ID: 30928346
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura.
Sargentini-Maier ML; De Decker P; Tersteeg C; Canvin J; Callewaert F; De Winter H
Expert Rev Clin Pharmacol; 2019 Jun; 12(6):537-545. PubMed ID: 30977686
[No Abstract] [Full Text] [Related]
16. Thrombotic thrombocytopenic purpura in caplacizumab era - An individualized approach.
Sarode R
Transfus Apher Sci; 2023 Apr; 62(2):103682. PubMed ID: 36890095
[TBL] [Abstract][Full Text] [Related]
17. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
Abdelghany MT; Baggett MV
N Engl J Med; 2016 Jun; 374(25):2497. PubMed ID: 27332912
[No Abstract] [Full Text] [Related]
18. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
Peyvandi F; Callewaert F
N Engl J Med; 2016 Jun; 374(25):2497-8. PubMed ID: 27332911
[No Abstract] [Full Text] [Related]
19. ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP.
Völker LA; Kaufeld J; Miesbach W; Brähler S; Reinhardt M; Kühne L; Mühlfeld A; Schreiber A; Gaedeke J; Tölle M; Jabs WJ; Özcan F; Markau S; Girndt M; Bauer F; Westhoff TH; Felten H; Hausberg M; Brand M; Gerth J; Bieringer M; Bommer M; Zschiedrich S; Schneider J; Elitok S; Gawlik A; Gäckler A; Kribben A; Schwenger V; Schoenermarck U; Roeder M; Radermacher J; Bramstedt J; Morgner A; Herbst R; Harth A; Potthoff SA; von Auer C; Wendt R; Christ H; Brinkkoetter PT; Menne J
Blood Adv; 2020 Jul; 4(13):3093-3101. PubMed ID: 32634237
[TBL] [Abstract][Full Text] [Related]
20. Successful use of a second course of caplacizumab in relapsed thrombotic thrombocytopenic purpura.
Shaffer J; Grove A
Platelets; 2022 Jul; 33(5):790-791. PubMed ID: 34565299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]